{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T11:12:27Z","timestamp":1782645147322,"version":"3.54.5"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,6,23]],"date-time":"2021-06-23T00:00:00Z","timestamp":1624406400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,6,23]],"date-time":"2021-06-23T00:00:00Z","timestamp":1624406400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Women's Health"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>This study analyzed the changes of serum and pathological biomarkers during fertility-sparing therapy of endometrial cancer (EC) or endometrial atypical hyperplasia (EAH), to investigate their implications for early prediction of treatment efficacy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A retrospective analysis of EC or EAH patients who received fertility-sparing therapy between 2012 and 2016 was performed. Serum and endometrium sampling were obtained for each patient at three time points: at baseline, at 3\u20136\u00a0months' treatment and at the end of conservative treatment. Serum biomarkers including insulin resistance (HbA1c, HOMA-IR), sex hormones and thyroid hormones were measured. Meanwhile expression of endometrial pathological biomarkers including ER, PR, PRB and Ki-67 was also assessed by immunohistochemistry.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>For the 53 recruited patients, overall complete response, recurrence and pregnancy rates were 94%, 26% and 36.4%. During the treatment, the serum biomarkers of HOMA-IR remained stable, while pathological markers including PR, PRB and Ki67 diminished significantly. Patients who achieved remission faster had significant lower HOMA-IR level and higher PRB expression at baseline. We also found a more remarkable down-regulation of PRB related with faster remission. Further multivariate analysis confirmed that baseline HOMA-IR\u2009\u2265\u20092.5 negatively affected treatment time to remission (OR 0.206; p\u2009=\u20090.017). While marked reduction of PRB (\u2265\u200930%) at 3\u20136\u00a0months' treatment correlated with faster remission (OR 5.788; p\u2009=\u20090.010).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>For EC and EAH patients who received fertility-sparing therapy, baseline status of insulin resistance predicted poor response to progestin, while marked reduction of PRB following the initial 3\u20136\u00a0months' treatment predicted fast remission.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12905-021-01383-5","type":"journal-article","created":{"date-parts":[[2021,6,23]],"date-time":"2021-06-23T17:04:55Z","timestamp":1624467895000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Significance of serum and pathological biomarkers in fertility-sparing treatment for endometrial cancer or atypical hyperplasia: a retrospective cohort study"],"prefix":"10.1186","volume":"21","author":[{"given":"Yiqin","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaobo","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huixin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danhua","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianliu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,23]]},"reference":[{"issue":"6","key":"1383_CR1","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1097\/IGC.0000000000000723","volume":"26","author":"Y Qin","year":"2016","unstructured":"Qin Y, Yu Z, Yang J, Cao D, Yu M, Wang Y, Shen K. Oral progestin treatment for early-stage endometrial cancer: a systematic review and meta-analysis. Int J Gynecol Cancer. 2016;26(6):1081\u201391.","journal-title":"Int J Gynecol Cancer"},{"issue":"10023","key":"1383_CR2","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1016\/S0140-6736(15)00130-0","volume":"387","author":"P Morice","year":"2016","unstructured":"Morice P, Leary A, Creutzberg C, Abu-Rustum N, Darai E. Endometrial cancer. Lancet. 2016;387(10023):1094\u2013108.","journal-title":"Lancet"},{"issue":"1","key":"1383_CR3","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.ygyno.2014.07.095","volume":"135","author":"C Liao","year":"2014","unstructured":"Liao C, Zhang D, Mungo C, Tompkins DA, Zeidan AM. Is diabetes mellitus associated with increased incidence and disease-specific mortality in endometrial cancer? A systematic review and meta-analysis of cohort studies. Gynecol Oncol. 2014;135(1):163\u201371.","journal-title":"Gynecol Oncol"},{"issue":"3","key":"1383_CR4","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1007\/s12253-019-00684-3","volume":"26","author":"A Raffone","year":"2020","unstructured":"Raffone A, Travaglino A, Saccone G, D\u2019Alessandro P, Arduino B, Mascolo M, De Placido G, Insabato L, Zullo F. Diabetes mellitus is associated with occult cancer in endometrial hyperplasia. Pathol Oncol Res. 2020;26(3):1377\u201384.","journal-title":"Pathol Oncol Res"},{"issue":"1","key":"1383_CR5","doi-asserted-by":"publisher","first-page":"190","DOI":"10.14336\/AD.2018.0224","volume":"10","author":"Y Wang","year":"2019","unstructured":"Wang Y, Zhou R, Wang J. Relationship between hypothyroidism and endometrial cancer. Aging Dis. 2019;10(1):190\u20136.","journal-title":"Aging Dis"},{"issue":"1","key":"1383_CR6","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.ygyno.2018.12.018","volume":"153","author":"KJ Jerzak","year":"2019","unstructured":"Jerzak KJ, Duska L, MacKay HJ. Endocrine therapy in endometrial cancer: an old dog with new tricks. Gynecol Oncol. 2019;153(1):175\u201383.","journal-title":"Gynecol Oncol"},{"key":"1383_CR7","unstructured":"Kurman R, Carcangiu M, Herrington C, Young R, Kurman R, Carcangiu M, Herrington C, Young R: WHO Classification of tumors of female reproductive organs. 2014."},{"issue":"6","key":"1383_CR8","doi-asserted-by":"publisher","first-page":"e90","DOI":"10.3802\/jgo.2019.30.e90","volume":"30","author":"A Mitsuhashi","year":"2019","unstructured":"Mitsuhashi A, Habu Y, Kobayashi T, Kawarai Y, Ishikawa H, Usui H, Shozu M. Long-term outcomes of progestin plus metformin as a fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer patients. J Gynecol Oncol. 2019;30(6):e90.","journal-title":"J Gynecol Oncol"},{"issue":"7","key":"1383_CR9","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.2337\/dc10-0666","volume":"33","author":"E Giovannucci","year":"2010","unstructured":"Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Habel LA, Pollak M, Regensteiner JG, Yee D. Diabetes and cancer: a consensus report. Diabetes Care. 2010;33(7):1674\u201385.","journal-title":"Diabetes Care"},{"key":"1383_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/cas.12043","volume":"104","author":"K Shikata","year":"2013","unstructured":"Shikata K, Ninomiya T, Kiyohara Y. Diabetes mellitus and cancer risk: review of the epidemiological evidence. Cancer Sci. 2013;104:1.","journal-title":"Cancer Sci"},{"issue":"11","key":"1383_CR11","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1080\/09513590.2019.1624716","volume":"35","author":"A Raffone","year":"2019","unstructured":"Raffone A, Travaglino A, Saccone G, Di Maio A, Mollo A, Mascolo M, De Rosa R, De Placido G, Insabato L, Zullo F. Diabetes mellitus and responsiveness of endometrial hyperplasia and early endometrial cancer to conservative treatment. Gynecol Endocrinol. 2019;35(11):932\u20137.","journal-title":"Gynecol Endocrinol"},{"issue":"3","key":"1383_CR12","doi-asserted-by":"publisher","first-page":"e35","DOI":"10.3802\/jgo.2018.29.e35","volume":"29","author":"B Yang","year":"2018","unstructured":"Yang B, Xie L, Zhang H, Zhu Q, Du Y, Luo X, Chen X. Insulin resistance and overweight prolonged fertility-sparing treatment duration in endometrial atypical hyperplasia patients. J Gynecol Oncol. 2018;29(3):e35.","journal-title":"J Gynecol Oncol"},{"issue":"8","key":"1383_CR13","doi-asserted-by":"publisher","first-page":"e69001","DOI":"10.1371\/journal.pone.0069001","volume":"8","author":"C-F Wang","year":"2013","unstructured":"Wang C-F, Zhang G, Zhao L-J, Qi W-J, Li X-P, Wang J-L, Wei L-H. Overexpression of the insulin receptor isoform A promotes endometrial carcinoma cell growth. PLoS ONE. 2013;8(8):e69001.","journal-title":"PLoS ONE"},{"issue":"6","key":"1383_CR14","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/j.ajog.2011.05.042","volume":"205","author":"RE Schmandt","year":"2011","unstructured":"Schmandt RE, Iglesias DA, Co NN, Lu KH. Understanding obesity and endometrial cancer risk: opportunities for prevention. Am J Obstet Gynecol. 2011;205(6):518\u201325.","journal-title":"Am J Obstet Gynecol"},{"issue":"8","key":"1383_CR15","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1016\/j.cellsig.2012.03.012","volume":"24","author":"V Bartella","year":"2012","unstructured":"Bartella V, De Marco P, Malaguarnera R, Belfiore A, Maggiolini M. New advances on the functional cross-talk between insulin-like growth factor-I and estrogen signaling in cancer. Cell Signal. 2012;24(8):1515\u201321.","journal-title":"Cell Signal"},{"issue":"1","key":"1383_CR16","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.tem.2011.09.005","volume":"23","author":"TN Le","year":"2012","unstructured":"Le TN, Nestler JE, Strauss JF, Wickham EP. Sex hormone-binding globulin and type 2 diabetes mellitus. Trends Endocrinol Metab. 2012;23(1):32\u201340.","journal-title":"Trends Endocrinol Metab"},{"key":"1383_CR17","doi-asserted-by":"publisher","first-page":"41404","DOI":"10.1038\/srep41404","volume":"7","author":"M Dai","year":"2017","unstructured":"Dai M, Zhu X-L, Liu F, Xu Q-Y, Ge Q-L, Jiang S-H, Yang X-M, Li J, Wang Y-H, Wu Q-K, et al. Cholesterol synthetase DHCR24 induced by insulin aggravates cancer invasion and progesterone resistance in endometrial carcinoma. Sci Rep. 2017;7:41404.","journal-title":"Sci Rep"},{"issue":"9","key":"1383_CR18","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1111\/aogs.13587","volume":"98","author":"A Travaglino","year":"2019","unstructured":"Travaglino A, Raffone A, Saccone G, Insabato L, Mollo A, De Placido G, Zullo F. Immunohistochemical predictive markers of response to conservative treatment of endometrial hyperplasia and early endometrial cancer: a systematic review. Acta Obstet Gynecol Scand. 2019;98(9):1086\u201399.","journal-title":"Acta Obstet Gynecol Scand"},{"issue":"2","key":"1383_CR19","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.ygyno.2005.10.030","volume":"101","author":"AB Vereide","year":"2006","unstructured":"Vereide AB, Kaino T, Sager G, Arnes M, \u00d8rbo A. Effect of levonorgestrel IUD and oral medroxyprogesterone acetate on glandular and stromal progesterone receptors (PRA and PRB), and estrogen receptors (ER-alpha and ER-beta) in human endometrial hyperplasia. Gynecol Oncol. 2006;101(2):214\u201323.","journal-title":"Gynecol Oncol"},{"key":"1383_CR20","doi-asserted-by":"crossref","unstructured":"Raffone A, Travaglino A, Zullo FM, Gencarelli A, Micheli M, Miranda S, De Franciscis P, Insabato L, Di Spiezio Sardo A, Zullo F et al: Predictive Accuracy of progesterone receptor B in young women with atypical endometrial hyperplasia and early endometrial cancer treated with hysteroscopic resection plus LNG-IUD Insertion. J Minim Invasive Gynecol 2020.","DOI":"10.1016\/j.jmig.2020.10.009"},{"issue":"1","key":"1383_CR21","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.ygyno.2015.10.023","volume":"140","author":"HD Reyes","year":"2016","unstructured":"Reyes HD, Carlson MJ, Devor EJ, Zhang Y, Thiel KW, Samuelson MI, McDonald M, Yang S, Stephan J-M, Savage EC, et al. Downregulation of FOXO1 mRNA levels predicts treatment failure in patients with endometrial pathology conservatively managed with progestin-containing intrauterine devices. Gynecol Oncol. 2016;140(1):152\u201360.","journal-title":"Gynecol Oncol"},{"issue":"8","key":"1383_CR22","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1111\/aogs.13586","volume":"98","author":"A Raffone","year":"2019","unstructured":"Raffone A, Travaglino A, Saccone G, Mollo A, De Placido G, Insabato L, Zullo F. Should progesterone and estrogen receptors be assessed for predicting the response to conservative treatment of endometrial hyperplasia and cancer? A systematic review and meta-analysis. Acta Obstet Gynecol Scand. 2019;98(8):976\u201387.","journal-title":"Acta Obstet Gynecol Scand"},{"issue":"1","key":"1383_CR23","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.ygyno.2013.11.033","volume":"132","author":"CC Gunderson","year":"2014","unstructured":"Gunderson CC, Dutta S, Fader AN, Maniar KP, Nasseri-Nik N, Bristow RE, Diaz-Montes TP, Palermo R, Kurman RJ. Pathologic features associated with resolution of complex atypical hyperplasia and grade 1 endometrial adenocarcinoma after progestin therapy. Gynecol Oncol. 2014;132(1):33\u20137.","journal-title":"Gynecol Oncol"},{"issue":"3","key":"1383_CR24","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.ygyno.2015.10.015","volume":"139","author":"Y-F Yang","year":"2015","unstructured":"Yang Y-F, Liao Y-Y, Liu X-L, Su S-G, Li L-Z, Peng N-F. Prognostic factors of regression and relapse of complex atypical hyperplasia and well-differentiated endometrioid carcinoma with conservative treatment. Gynecol Oncol. 2015;139(3):419\u201323.","journal-title":"Gynecol Oncol"},{"issue":"6","key":"1383_CR25","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1097\/PGP.0000000000000177","volume":"33","author":"RJ Zaino","year":"2014","unstructured":"Zaino RJ, Brady WE, Todd W, Leslie K, Fischer EG, Horowitz NS, Mannel RS, Walker JL, Ivanovic M, Duska LR. Histologic effects of medroxyprogesterone acetate on endometrioid endometrial adenocarcinoma: a Gynecologic Oncology Group study. Int J Gynecol Pathol. 2014;33(6):543\u201353.","journal-title":"Int J Gynecol Pathol"}],"container-title":["BMC Women's Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12905-021-01383-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12905-021-01383-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12905-021-01383-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,23]],"date-time":"2021-06-23T17:05:21Z","timestamp":1624467921000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcwomenshealth.biomedcentral.com\/articles\/10.1186\/s12905-021-01383-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,23]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1383"],"URL":"https:\/\/doi.org\/10.1186\/s12905-021-01383-5","relation":{},"ISSN":["1472-6874"],"issn-type":[{"value":"1472-6874","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,23]]},"assertion":[{"value":"20 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"We confirm that all methods were carried out in accordance with relevant guidelines and regulations. The protocol for this study was approved by the Independent Ethics Committee (IEC) of Peking University People\u2019s Hospital (Approval Number: 2016PHB054-01). Informed consent was obtained from all the patients recruited.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"252"}}